OTCM
AWKNF
Market cap2mUSD
Dec 13, Last price
0.07USD
Name
Awakn Life Sciences Corp
Chart & Performance
P/E
—
P/S
42.79
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
87k
-94.16%
Net income
-5m
L-44.19%
CFO
-2m
L-67.66%
Profile
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑01 | 2023‑01 | 2022‑01 | 2021‑01 | |
| Income | ||||
Revenues | 87 -94.16% | 1,495 533.52% | ||
Cost of revenue | 4,014 | 7,637 | ||
Unusual Expense (Income) | ||||
NOPBT | (3,926) | (6,142) | ||
NOPBT Margin | ||||
Operating Taxes | (509) | |||
Tax Rate | ||||
NOPAT | (3,926) | (5,633) | ||
Net income | (5,103) -44.19% | (9,143) -42.66% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 2,656 | 5,972 | ||
BB yield | ||||
| Debt | ||||
Debt current | 387 | |||
Long-term debt | 3,138 | |||
Deferred revenue | ||||
Other long-term liabilities | 71 | |||
Net debt | (407) | 2,974 | ||
| Cash flow | ||||
Cash from operating activities | (2,381) | (7,364) | ||
CAPEX | (95) | |||
Cash from investing activities | (20) | (95) | ||
Cash from financing activities | 2,456 | 6,404 | ||
FCF | (621) | (3,735) | ||
| Balance | ||||
Cash | 407 | 551 | ||
Long term investments | ||||
Excess cash | 403 | 476 | ||
Stockholders' equity | (9,024) | (50) | ||
Invested Capital | 7,493 | 2,330 | ||
ROIC | ||||
ROCE | 256.59% | |||
| EV | ||||
Common stock shares outstanding | 29,068 | 25,203 | ||
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | (3,908) | (5,538) | ||
EV/EBITDA | ||||
Interest | 267 | |||
Interest/NOPBT | ||||